FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
Laa aaaaaaaaa	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Jones Edward Raymond					2. Issuer Name and Ticker or Trading Symbol Cytosorbents Corp [CTSO]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 04/02/2024								Officer below)	(give title	Othe below	(specify		
C/O CYTOSORBENTS CORPORATION 305 COLLEGE ROAD EAST					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) PRINCE	TON N	J	08540			Dula 40h 5 4(a) Transantian la disetion								Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									ed to satisfy					
		Tal	ole I - Nor	ı-Deri	vativ	e Se	curitie	s Ac	quired, D	ispose	d c	of, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date		Date,	Code (In			ed (A) or str. 3, 4 and	5. Amoun Securities Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	/ Amo	Amount (A) or (D)		Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		d	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form: Direct (I or Indirect) (I) (Instr	Beneficial Ownership ct (Instr. 4)		
				(Code	v	(A)		Date Exercisable	Expiration Date	on	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$0.955	04/02/2024			A		22,000		(1)	04/02/20)34	Common Stock	\$22,000	(1)	22,000	D			

Explanation of Responses:

1. These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

/s/ Kathleen P. Bloch attorneyin-fact for Edward R. Jones

04/04/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.